Loading stock data…
$23.71-0.03 (-0.13%)
Avalyn Pharma Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — |
| Operating Income | -$31.29M↓ | -$27.91M↓ | -$21.78M↓ | -$18.72M |
| Net Income | -$28.93M↓ | -$26.87M↓ | -$20.19M↓ | -$17.50M |
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of...